AeroNeph Therapeutics Announces Search for Strategic Partners for Novel Drugs for Renal Disease
Birmingham, Alabama, and London, England, XX September 2022 – AeroNeph Therapeutics (“AeroNeph”; www.aeroneph.com), a pioneer in discovery of renal disease assets, has announced its corporate launch in the USA.
AeroNeph has acquired its drug candidates from preclinical CRO Discovery Biomed who have used a revolutionary human disease approach to drug discovery; Discovery Biomed was acquired by Eurofins Discovery in July 2022, a leading global CRO.
AeroNeph’s focus is on Polycystic Kidney Disease, Chronic Kidney Disease and Lupus Nephritis.
AeroNeph is seeking strategic industry partners to collaborate/partner/license its 3 R&D programs, with a strong focus on Human Renal Disease for their advancement and continued preclinical and clinical development.
Aeroneph has acquired a range of preclinical drug assets which arose from Discovery Biomed’s unique human cell discovery program and intends to progress these into the clinic. Their asset portfolio includes molecules focused on:
· DBM 701 for Human Genetic Renal and Respiratory Diseases (PKD, CF, etc.)
· ADN Inducers for Dyslipidemia and Other Diabetes and Obesity Complications
· STING Inhibitors for Lupus Nephritis, SAVI (niche genetic autoimmune diseases)
Following a strategic review of its clinical and commercial development options, AeroNeph has appointed The Sage Group to lead the partnering program for its leading candidates capable of modulating renal disease including Chronic Kidney Disease, Polycystic Kidney Disease, and Lupus Nephritis.
AeroNeph is a rapidly growing, US-based pharmaceutical discovery company, focused on using human cell models for drug discovery.
The Company is led scientifically by Dr. Erik Schwiebert, Consulting CEO, and Dr. John Strieff, Consulting CSO.
AeroNeph has long lasting and issued patents protecting its discoveries and its pipeline.
Erik Schwiebert, Consulting CEO of AeroNeph, said “Our pipeline drug candidates have the potential to become ground-breaking drugs in the control of renal diseases. We look forward to working with partners seeking these valuable assets which have been proven in human cell models of disease, and who wish to partner with us to develop these assets in clinical and commercial respects.”
For more information about AeroNeph Therapeutics and partnering opportunities for its pipeline drug candidates, please contact:
Dr. Bill Mason The Sage Group The Stockyard Creake Road, Syderstone PE31 8SG UK Tel: +44 (0) 7785 950134 firstname.lastname@example.org
Wayne Pambianchi The Sage Group Inc. 1802 Route 31 North #381 Clinton New Jersey 08809 USA Phone: +1 908 2306170 email@example.com
About AeroNeph Therapeutics
AeroNeph Therapeutics is a leading [[[Erik to provide words here]]]
About The Sage Group, Inc.
The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in USA, Europe, Israel and Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million.